About this episode
1) Management of headache and 2) Topic of the month: Aphasia. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Professor Peter Goadsby about his paper on management of headache. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about electrodiagnostic features of axonal neuropathy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs for the next part of our discussion on aphasias for our Lesson of the Week. The participants had nothing to disclose except Professor Goadsby, Drs. Overman, Espay and Josephs. Prof. Goadsby has served as a consultant for or served on a scientific advisory board for Advanced Bionics, Allergan, Inc., Almirall, Amgen, ATI, AstraZeneca, Belgian Research Council, Boehringer Ingelheim, Bristol-Myers Squibb, Boston Scientific, CoLucid Pharmaceuticals, Coherex Medical, Inc., Eli Lilly & Company, Fidelity Foundation, GlaxoSmithKline, Johnson & Johnson, Kalypsys Inc., Medtronic, Inc., MAP Pharmaceuticals, Inc., Migraine Research Foundation, Migraine Trust, Minster Pharmaceuticals plc, Medical Research Council-UK, Merck & Co., Inc., the NIH/ NINDS (Consultant); Netherlands Research Council, Neuralieve, NeurAxon Inc. NeuroTherapeutics Pharma, Organisation for Understanding Cluster Headache-UK and US, and Pfizer Inc; receives royalties from the publication of Mechanism and Management of Headache, 7th ed. (Elsevier, 2005); and has received research support from GlaxoSmithKline, Neuralieve, Merck & Co., Inc., Johnson & Johnson, and MAP Pharmaceuticals, Inc. Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.Dr. Josephs is funded by R01- DC010367 (PI), the Dana Foundation (PI), and the Morris K. Udall PD Research Center of Excellence NIH/NINDS P50 NS40256 (Co-I).